financetom
Business
financetom
/
Business
/
Albemarle's cost cuts, steady volumes fuel smaller loss amid weak lithium prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Albemarle's cost cuts, steady volumes fuel smaller loss amid weak lithium prices
Nov 6, 2025 6:53 AM

(Reuters) -Albemarle reported a smaller-than-expected loss for the third quarter on Wednesday, as the lithium producer's tight leash on costs and resilient sales volumes softened the squeeze from persistently low prices for the metal.

Shares of the Charlotte, North Carolina-based company rose nearly 4% in Thursday morning trading.

Albemarle has sharpened its focus on efficiency and cash preservation as the industry grapples with the pressure on prices from an oversupplied market as Chinese producers have increased output despite moderating demand from electric vehicle makers for the critical component. Executives said that demand has started to improve.

"Overall demand for lithium remains robust, up 30% year to date," CEO Kent Masters told investors on a Thursday conference call to discuss the results. Albemarle kept its 2025 forecast for sales to be at the higher end of an estimate range for sales of $4.9 billion to $5.2 billion. 

The company has implemented extensive cost-cutting measures to reduce debt and strengthen financial flexibility, including divestments and operational streamlining. Masters said that would continue.

Albemarle has rationalized its operations, placing its Chengdu lithium hydroxide facility into care and maintenance, and last month announced plans to sell stakes in some businesses in deals worth $660 million.

The company on Wednesday lowered its annual capital spending forecast to around $600 million, down 65% from $1.7 billion in 2024, and said it expects to generate positive free cash flow of $300 million to $400 million this year.

The lithium giant expects full-year results at the upper end of its previously disclosed $9 per kilogram lithium carbonate equivalent forecast, supported by stronger-than-expected energy storage volumes and favorable pricing

The company reported an adjusted loss of 19 cents per share for the quarter ended September 30, compared with analysts' average estimate for a loss of 78 cents per share, according to data compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oil Trading Higher as the U.S. Driving Season Begins While OPEC+ is Expected to Keep Quota Cuts in Place
Oil Trading Higher as the U.S. Driving Season Begins While OPEC+ is Expected to Keep Quota Cuts in Place
May 28, 2024
08:56 AM EDT, 05/28/2024 (MT Newswires) -- Oil prices rose early on Tuesday on expectations the start of the U.S. driving season will offer a robust boost to demand ahead of a weekend meeting of OPEC+ that is expected to keep supply restrictions in place. West Texas Intermediate crude oil for July delivery was last seen up US$1.37 to US$79.09...
Energy Transfer expands Permian presence with $3.25 bln acquisition of WTG Midstream
Energy Transfer expands Permian presence with $3.25 bln acquisition of WTG Midstream
May 28, 2024
May 28 (Reuters) - Energy Transfer ( ET ) said on Tuesday it would buy WTG Midstream Holdings in a deal valued at about $3.25 billion, the latest in the pipeline operator's string of deals since last year aimed at expanding its gas transportation and processing network in the Permian Basin. The deal will be comprised of $2.45 billion in...
Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million
Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million
May 28, 2024
08:56 AM EDT, 05/28/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Tuesday that it has agreed to sell its rights to a 15% royalty on the potential US net sales of Servier's vorasidenib to Royalty Pharma ( RPRX ) for $905 million. Under the terms, Agios said it will receive the $905 million payment upfront upon approval of...
Organigram Signs Three-Year Supply Agreement With Avida Medical in UK
Organigram Signs Three-Year Supply Agreement With Avida Medical in UK
May 28, 2024
08:55 AM EDT, 05/28/2024 (MT Newswires) -- Organigram Holdings ( OGI ) said Tuesday it has signed a three-year supply agreement with Avida Medical, a full-service medical cannabis and specials medicines production company, in the UK. Under the terms, the company intends to provide Avida Medical with 1,700 kilograms of dried cannabis flower in the UK for three years, Organigram...
Copyright 2023-2026 - www.financetom.com All Rights Reserved